Colorectal Cancer

The FDA updated its safety labeling for capecitabine and 5-FU to reflect that patients with certain genetic variants risk severe or fatal toxicities.

Findings from the phase 3 COMMIT study show that adding mFOLFOX6 and bevacizumab to atezolizumab significantly improves PFS in patients with dMMR/MSI-H mCRC.

The frontline combination of encorafenib, cetuximab, and FOLFIRI yielded significant improvement vs SOC in BRAF V600E-mutated metastatic colorectal cancer.

Data link physical activity with reduced cancer-related fatigue in patients with colorectal cancer.

Findings from a real-world, head-to-head comparison show greater colorectal cancer risk reduction and safety with the use of a GLP-1RA vs aspirin.

What should nurses know about treating patients with KRAS G12C-mutated metastatic colorectal cancer using adagrasib and cetuximab?

Emily Shelby, MSN, FNP-C, emphasized that referrals to other specialties is key to managing heavily pretreated patients with metastatic colorectal cancer.

Ponsegromab increased body weight in patients with cancer-associated cachexia, yielding greater improvement in those who received ponsegromab previously.

Ronald Bleday, MD, discusses how nurses support a step-wise model to minimize opioid use after colorectal surgery while ensuring safe pain control.

A significant reduction of opioid use in patients after colorectal surgery was supported by clinician and patient compliance, says Ronald Bleday, MD.

In a phase 1 study, ELI-002 2P improved relapse-free survival in pancreatic and colorectal cancer, with stronger benefit in patients with T-cell responses.

Panitumumab plus FOLFIRINOX or mFOLFOX6 failed to yield meaningful responses in liver-limited, RAS/BRAF wild-type unresectable mCRC.

Adjuvant aspirin did not reduce recurrence or improve survival in patients with CRC liver metastases, phase 3 data showed at the 2025 ASCO Meeting.

Biomarker data from CodeBreaK 300 suggest DNA and RTK pathway alterations may underlie resistance to sotorasib plus panitumumab in CRC.

Advanced practice providers have the opportunity to instill hope in patients through education and personalized care.

Lasting survival benefits vs chemotherapy or monotherapy were achieved with nivolumab and ipilimumab for patients with MSI-H/ dMMR metastatic colorectal cancer.

Patients with stage III and high-risk stage II colon cancer who participated in an exercise program saw improved disease-free and overall survival.

Atezolizumab plus chemotherapy reduced risk of death or recurrence by 50% compared with chemotherapy alone for patients with stage III dMMR colon cancer.

Patients with stage III resected colon cancer had lower risk of death with less inflammatory diets and more regular physical activity.

Encorafenib and cetuximab plus mFOLFOX6 increased progression-free survival for patients with metastatic colorectal cancer harboring BRAF V600E mutations.

The addition of bevacizumab to capecitabine produced favorable efficacy and safety data for older patients with metastatic colorectal cancer.

Approvals in oncology during April included treatments for breast cancer, colorectal cancer, and more.

The accelerated approval for nivolumab monotherapy in unresectable/metastatic MSI-H/dMMR CRC has also been converted to regular approval.

Panitumumab plus ipilimumab and nivolumab signaled complete or partial response in 18 patients with KRAS/NRAS/BRAF wild-type MSS mCRC at the 12-week mark.